Skip to main content
SpringerLink
Log in

Conversion from intravenous maxacalcitol to oral vitamin D in secondary hyperparathyroidism management

  • Letter to the editor
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17(3):247–88.

    Article  Google Scholar 

  2. Hirata M, Endo K, Katsumata K, Ichikawa F, Kubodera N, Fukagawa M. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action. Nephrol Dial Transpl. 2002;17(Suppl 10):S41–5.

    Article  Google Scholar 

  3. Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology (Carlton). 2011;16(3):277–84.

    Article  CAS  Google Scholar 

  4. Thadhani RI, Rosen S, Ofsthun NJ, Usvyat LA, Dalrymple LS, Maddux FW, et al. Conversion from intravenous vitamin D analogs to oral calcitriol in patients receiving maintenance hemodialysis. Clin J Am Soc Nephrol. 2020;15(3):384–91.

    Article  CAS  Google Scholar 

  5. Kumar J, Tran NT, Schomberg J, Streja E, Kalantar-Zadeh K, Pahl M. Successful conversion from parenteral paricalcitol to pulse oral calcitriol for the management of secondary hyperparathyroidism in hemodialysis patients. J Ren Nutr. 2016;26(4):265–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Internal Medicine, International University of Health and Welfare School of Medicine, 13-1 Higashi-Kaigan-Cho, Atami, Shizuoka, 413-0012, Japan

    Masayuki Tanemoto

  2. Dialysis Unit, Shin-Kuki General Hospital, Saitama, Japan

    Masayuki Tanemoto & Yoji Katsuoka

Authors
  1. Masayuki Tanemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoji Katsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Tanemoto.

Ethics declarations

Conflict of interest

All the authors have no conflicts of interest.

Ethical concerns

This study was approved by the Ethics Committee of Shin-Kuki General Hospital (Approved number 0002). For this type of study, formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanemoto, M., Katsuoka, Y. Conversion from intravenous maxacalcitol to oral vitamin D in secondary hyperparathyroidism management. Clin Exp Nephrol 26, 97–98 (2022). https://doi.org/10.1007/s10157-021-02138-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-021-02138-0

Keywords

Search

Navigation